SRPT is an asset play, it is a commercial stage biopharmaceutical company and has more than 40 programs at various stages of discovery. It has 3 products that are in commercial phase, EXONDYS 51, VYONDYS 53, and AMONDYS 45. It is expected to grow revenue at a rate of 35% for the next 4 years to 3.5B. Fair value stands at around $130 per share for now, however it represents a huge opportunity ahead if a few of its assets play out. 

Technically it has support at its 200 ma of $81.55 and resistance at $135. Maybe an Iron Condor for now?